About Serum paraoxonase/arylesterase 1
Serum paraoxonase/arylesterase 1 (PON1) is a protein
from Homo sapiens identified by UniProt accession
P27169, 355 residues long.
MolForge cross-references it against 0 known binders and
613 disease associations.
Target properties
| Protein name | Serum paraoxonase/arylesterase 1 |
| UniProt accession | P27169 |
| Gene | PON1 |
| Organism | Homo sapiens |
| Length | 355 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (613)
Diseases linked to this target (Open Targets).
- amyotrophic lateral sclerosis · score 0.40
- aspartate aminotransferase, cytoplasmic measurement · score 0.39
- arylesterase enzyme measurement · score 0.38
- Amyotrophic lateral sclerosis · score 0.37
- leucine carboxyl methyltransferase 1 measurement · score 0.31
- blood protein measurement · score 0.31
- atopic eczema · score 0.31
- metabolite measurement · score 0.31
- protein measurement · score 0.30
- stem Cell Factor measurement · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P27169-F1 | alphafold | PREDICTED | 96.78 | — |
Amino-acid sequence (355 residues)
MAKLIALTLL GMGLALFRNH QSSYQTRLNA LREVQPVELP NCNLVKGIET GSEDLEILPN GLAFISSGLK YPGIKSFNPN SPGKILLMDL NEEDPTVLEL GITGSKFDVS SFNPHGISTF TDEDNAMYLL VVNHPDAKST VELFKFQEEE KSLLHLKTIR HKLLPNLNDI VAVGPEHFYG TNDHYFLDPY LQSWEMYLGL AWSYVVYYSP SEVRVVAEGF DFANGINISP DGKYVYIAEL LAHKIHVYEK HANWTLTPLK SLDFNTLVDN ISVDPETGDL WVGCHPNGMK IFFYDSENPP ASEVLRIQNI LTEEPKVTQV YAENGTVLQG STVASVYKGK LLIGTVFHKA LYCEL
Explore Serum paraoxonase/arylesterase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets